Today: 8 April 2026
Subscribe
Browse Category

Biotechnology 2 February 2026 - 7 April 2026

Soleno Therapeutics Pulls Europe Drug Filing After $2.9 Billion Neurocrine Deal

Soleno Therapeutics Pulls Europe Drug Filing After $2.9 Billion Neurocrine Deal

Soleno Therapeutics withdrew its European filing for VIOKAT on Tuesday, halting a regulatory review that was expected to conclude in 2026. The move came one day after Neurocrine Biosciences agreed to acquire Soleno for $2.9 billion in cash, or $53 a share. Vykat XR, Soleno’s only marketed product, generated $190.4 million in 2025 U.S. sales. Neurocrine said it has no immediate plans for a European launch.
7 April 2026
···
BioCryst (BCRX) stock price dips premarket as new navenibart HAE data lands; Cowen talk next

BioCryst (BCRX) stock price dips premarket as new navenibart HAE data lands; Cowen talk next

BioCryst Pharmaceuticals shares fell 2.9% to $8.50 premarket Monday after new clinical data on its hereditary angioedema drug pipeline. Interim results from the ALPHA-SOLAR study showed navenibart reduced mean monthly HAE attacks by 91% among 29 patients, with one discontinuation due to cancer. The company reaffirmed 2026 revenue guidance for ORLADEYO and expects a Phase 3 navenibart filing by late 2027.
2 March 2026
·
Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears

Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears

Eli Lilly shares rose 2.93% to $1,051.99 Friday, outperforming a falling market. Full results from a diabetes trial showed Lilly’s oral drug orforglipron caused more nausea and discontinuations than Novo Nordisk’s Rybelsus, but produced greater A1C and weight reduction. The 52-week study involved 1,698 patients. Novo plans to cut U.S. list prices for Ozempic and Wegovy by up to 50% starting in 2027.
28 February 2026
···
CRISPR Therapeutics stock whipsaws again as takeover talk resurfaces — here’s what to watch

CRISPR Therapeutics stock whipsaws again as takeover talk resurfaces — here’s what to watch

CRISPR Therapeutics shares fell 1.9% to $60.55 in premarket trading Friday after an 11.85% surge Thursday on renewed takeover speculation flagged by Betaville, The Fly reported. The company reported $116 million in 2025 Casgevy revenue and ended the year with $1.98 billion in cash. Management is set to appear at investor conferences starting March 2.
27 February 2026
···
Stoke Therapeutics stock swings premarket after Wolfe starts coverage with $40 target (STOK)

Stoke Therapeutics stock swings premarket after Wolfe starts coverage with $40 target (STOK)

Stoke Therapeutics shares dropped 1.2% to $35.80 in early premarket trading Tuesday, after a 5.7% gain the previous session. Wolfe Research began coverage with an “Outperform” rating and a $40 price target. Investors are watching for updates on the company’s Phase 3 Dravet syndrome trial with Biogen. About 21.6% of Stoke’s float is sold short, according to MarketBeat.
24 February 2026
···
Gossamer Bio stock tumbles again premarket as Phase 3 PAH miss rewrites the story

Gossamer Bio stock tumbles again premarket as Phase 3 PAH miss rewrites the story

Gossamer Bio shares traded near $0.42 in early premarket Tuesday after plunging about 80% when its main drug failed to meet the primary goal in a Phase 3 trial. The company said the study’s key endpoint improved by 13.3 meters but did not reach statistical significance. Analysts downgraded the stock and flagged risks around funding and regulatory timelines. Gossamer plans to meet the FDA and paused another study.
24 February 2026
···
Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Eli Lilly shares climbed nearly 5% late Monday after Novo Nordisk reported its obesity drug CagriSema underperformed Lilly’s Zepbound in a head-to-head trial. Novo’s U.S.-listed shares dropped over 16%. CagriSema showed 23% weight loss after 84 weeks, compared to 25.5% for Zepbound. The trial failed to prove CagriSema was not worse than tirzepatide on weight loss.
23 February 2026
····
GRAIL stock dives nearly 50% after UK Galleri trial misses key goal, raising FDA questions

GRAIL stock dives nearly 50% after UK Galleri trial misses key goal, raising FDA questions

GRAIL shares plunged nearly 50% to $51.00 after a UK trial showed its Galleri blood test missed the main goal of significantly improving early cancer detection. The study’s results complicate prospects for broad screening and reimbursement. Focus now shifts to U.S. regulators and Medicare-linked evidence. GRAIL reported Q4 revenue up 14% to $43.6 million and said its FDA approval submission is under review.
20 February 2026
··
Moderna stock price jumps late after earnings beat, but FDA flu setback hangs over MRNA

Moderna stock price jumps late after earnings beat, but FDA flu setback hangs over MRNA

Moderna shares climbed 5% to $42.23 in after-hours trading Friday after beating fourth-quarter revenue estimates and reaffirming its 2026 growth outlook. The FDA refused to file Moderna’s flu vaccine application, prompting the company to seek a Type A meeting. The flu shot is under review in Europe, Canada, and Australia. Moderna reported Q4 revenue of $678 million and a $2.11 per share loss.
13 February 2026
····
Roche share price set for Monday test after MS drug fenebrutinib data lands

Roche share price set for Monday test after MS drug fenebrutinib data lands

Roche said its experimental MS drug fenebrutinib met the main goal in a late-stage study for primary progressive multiple sclerosis, showing “non-inferiority” to Ocrevus but with more frequent, reversible liver enzyme elevations and a higher share of fatal cases. Roche shares last closed down 0.6% at 356.40 francs. Investors await Monday’s webcast for more data and filing plans.
8 February 2026
····
Eli Lilly stock rises after FDA steps up crackdown on GLP-1 copycats

Eli Lilly stock rises after FDA steps up crackdown on GLP-1 copycats

Eli Lilly shares climbed 3.7% in after-hours trading after the FDA announced plans to restrict GLP-1 ingredients in unapproved compounded drugs. Hims & Hers shares dropped nearly 12% after being referred for a Justice Department probe. Investors are watching for details on enforcement and pricing pressure as the market reacts to moves against copycat obesity drugs.
7 February 2026
···
Illumina (ILMN) stock slides 10% after 2026 outlook puts China, research demand back in focus

Illumina (ILMN) stock slides 10% after 2026 outlook puts China, research demand back in focus

Illumina shares dropped 10.3% to $119.91 after the company forecast 2026 revenue of $4.5–$4.6 billion and non-GAAP EPS of $5.05–$5.20. Management cited progress in China but said approvals are still needed for instrument sales. Fourth-quarter revenue rose 5% to $1.16 billion, with ex-China revenue up 8%. The company expects 2026 organic revenue growth of 2–4% excluding China.
6 February 2026
···
Thermo Fisher stock price today: TMO nudges higher after Thursday drop as investors eye next week’s data

Thermo Fisher stock price today: TMO nudges higher after Thursday drop as investors eye next week’s data

Thermo Fisher shares rose 0.6% to $545.58 Friday afternoon, recovering some ground after a 4% drop Thursday. The move lagged the broader market, with the S&P 500 up 1.73%. Investors remain cautious amid weak academic research funding and uncertain lab order trends. Upcoming U.S. jobs and inflation data could affect rate expectations and valuations.
6 February 2026
··
TransCode Therapeutics stock jumps on FDA filing for Phase 2a colorectal cancer trial

TransCode Therapeutics stock jumps on FDA filing for Phase 2a colorectal cancer trial

TransCode Therapeutics shares surged nearly 19% Thursday after the company filed an amended IND application for a Phase 2a trial of TTX-MC138 in colorectal cancer patients. Trading volume hit 11.5 million shares, up from 8,500 the previous day. The dose-expansion study, set to begin in early 2026, will enroll up to 45 patients with positive ctDNA markers. The trial will run with Quantum Leap Healthcare Collaborative on the PRE-I-SPY platform.
5 February 2026
·
Amgen stock jumps 8% after earnings beat — what to know before Thursday’s open

Amgen stock jumps 8% after earnings beat — what to know before Thursday’s open

Amgen shares surged 8.2% to $366.20 Wednesday after quarterly earnings beat forecasts and the company issued a 2026 outlook above consensus. Investors focused on progress in Amgen’s MariTide obesity program, which could allow less frequent dosing. The company reported Q4 revenue of $9.9 billion and adjusted EPS of $5.29. Amgen plans $2.6 billion in 2026 capital spending and capped share buybacks at $3 billion.
5 February 2026
···
Abbott (ABT) stock price steadies after Barclays trims target; Exact Sciences vote is next key date

Abbott (ABT) stock price steadies after Barclays trims target; Exact Sciences vote is next key date

Abbott Laboratories shares edged up 0.1% to $109.43 after Barclays cut its price target to $142 but kept an Overweight rating. Nutrition sales fell 8.9% last quarter, and diagnostics dropped 2.5%. Exact Sciences shareholders will vote February 20 on Abbott’s planned $23 billion takeover. The deal is expected to close in the second quarter of 2026.
2 February 2026
···
1 2 3 … 16

Stock Market Today

  • Delta Air Lines Q1 Earnings Beat Estimates with $0.45 EPS on $13.75 Billion Revenue
    April 8, 2026, 9:14 AM EDT. Delta Air Lines reported first-quarter earnings of $0.45 per share, surpassing analyst expectations of $0.36. Revenue reached $13.75 billion, exceeding estimates by over 7%. This marks continued strength for Delta, with earnings surprises in all of the last four quarters. Shares have gained 17.6% year-to-date, outperforming the S&P 500's 9.2% rise. Despite strong results, the stock holds a Zacks Rank #3 (Hold) due to mixed earnings estimate revisions ahead. The company projects upcoming quarterly earnings of $2.33 per share on revenues of $15.56 billion, with the full fiscal year estimated at $6.53 EPS on $58.63 billion revenue. Industry trends and management commentary during the earnings call will be crucial in shaping near-term stock performance.

Latest article

Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

8 April 2026
The Sensex surged 2,946 points to 77,562.90 on Wednesday, its best day in five years, as a U.S.-Iran ceasefire and steady RBI rates pushed Indian markets higher. Brent crude fell 14.4% to $93.49 a barrel, easing pressure on the rupee, which rose 0.5% to 92.58 per dollar. All 16 major sectors gained, led by financials and auto stocks. The RBI kept its repo rate at 5.25% and forecast slower growth ahead.
Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

8 April 2026
Stock Yards Bank & Trust Co. increased its Netflix stake by 1,141.9% to 29,074 shares in Q4, while Ethos Capital Management disclosed a new 19,610-share position worth $1.84 million. The moves come ahead of Netflix’s April 16 earnings report and follow a Goldman Sachs upgrade to Buy with a $120 target. Insiders Reed Hastings and Greg Peters sold shares earlier this year under preset trading plans. Netflix last traded at $98.82.
Alphabet Stock (GOOG, GOOGL) Faces Split Fund Bets Ahead of Earnings After Fresh 13F Reports

Alphabet Stock (GOOG, GOOGL) Faces Split Fund Bets Ahead of Earnings After Fresh 13F Reports

8 April 2026
Zevenbergen Capital increased its Alphabet Class A share holdings by 27.4% in Q4, while Lombard Odier and Empirical Wealth Management reduced their Class C positions, according to April 7 filings. Alphabet will report first-quarter results on April 29. GOOG and GOOGL traded near $304 before Wednesday’s U.S. open. The filings reflect holdings as of December 31 and may not show current positions.
Nvidia Stock Edges Up, but Broadcom’s Google TPU Deal Raises Stakes in AI Chip Race

Nvidia Stock Edges Up, but Broadcom’s Google TPU Deal Raises Stakes in AI Chip Race

8 April 2026
Broadcom announced a multiyear deal to develop Google’s next-generation TPUs and supply AI rack components through 2031. Nvidia shares rose 0.3% premarket, while Broadcom jumped 6.3% after the news. Anthropic said it will access 3.5 gigawatts of TPU compute from 2027 and reported Claude’s run-rate revenue above $30 billion. Analysts say custom ASICs could begin taking AI inference share from Nvidia starting in 2027.
Go toTop